Cargando…

NMO-IgG: A Specific Biomarker for Neuromyelitis Optica

Neuromyelitis optica (NMO) is an inflammatory demyelinating disease that principally targets the optic nerves and spinal cord and often leads to severe disability and occasionally life threatening respiratory failure. Although its clinical manifestations overlap with those of multiple sclerosis (MS)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weinshenker, Brian G., Wingerchuk, Dean M., Pittock, Sean J., Lucchinetti, Claudia F., Lennon, Vanda A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2006
Materias:	Other
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851409/ https://www.ncbi.nlm.nih.gov/pubmed/17124341 http://dx.doi.org/10.1155/2006/586306

Ejemplares similares

Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders
por: Redenbaugh, Vyanka, et al.
Publicado: (2021)

Spectrum of sublytic astrocytopathy in neuromyelitis optica
por: Guo, Yong, et al.
Publicado: (2021)

Neuromyelitis optica pathology in rats following intraperitoneal injection of NMO-IgG and intracerebral needle injury
por: Asavapanumas, Nithi, et al.
Publicado: (2014)

Neuromyelitis optica (NMO) and autoimmune thyroiditis
por: Sudulagunta, Sreenivasa Rao, et al.
Publicado: (2015)

Effects of neuromyelitis optica–IgG at the blood–brain barrier in vitro
por: Takeshita, Yukio, et al.
Publicado: (2016)

Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity
por: Zekeridou, Anastasia, et al.
Publicado: (2019)

Autoimmune thyroiditis associated with neuromyelitis optica (NMO)
por: Sudulagunta, Sreenivasa Rao, et al.
Publicado: (2015)

Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders
por: Palace, Jacqueline, et al.
Publicado: (2019)

Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats
por: Kitic, Maja, et al.
Publicado: (2013)

Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO)
por: Vaknin-Dembinsky, Adi, et al.
Publicado: (2016)

Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica
por: Guo, Yong, et al.
Publicado: (2017)

NFκB signaling drives pro-granulocytic astroglial responses to neuromyelitis optica patient IgG
por: Walker-Caulfield, Margaret E., et al.
Publicado: (2015)

Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders
por: Asseyer, Susanna, et al.
Publicado: (2018)

Neuromyelitis optica-IgG testing in an Indian cohort with neuromyelitis optica and related demyelinating disorders: Our experience
por: Unni, Narayanan, et al.
Publicado: (2013)

An Atypical Presentation of Chronic Inflammatory Myelin Degeneration in Neuromyelitis Optica (NMO)
por: Allu, Sai Vishnu Vardhan, et al.
Publicado: (2023)

Aquaporin-4–binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2
por: Hinson, Shannon R., et al.
Publicado: (2008)

Plasmablasts as Migratory IgG-Producing Cells in the Pathogenesis of Neuromyelitis Optica
por: Chihara, Norio, et al.
Publicado: (2013)

Placebo-controlled study in neuromyelitis optica—Ethical and design considerations
por: Cree, Bruce AC, et al.
Publicado: (2015)

Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide
por: Hor, Jyh Yung, et al.
Publicado: (2020)

Vitamin D and Demyelinating Diseases: Neuromyelitis Optica (NMO) and Multiple Sclerosis (MS)
por: Rodney, Cady, et al.
Publicado: (2020)

Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain
por: Saadoun, Samira, et al.
Publicado: (2014)

Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD
por: Zeka, Bleranda, et al.
Publicado: (2016)

Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum
por: Weinshenker, Brian G, et al.
Publicado: (2023)

Identification of geraldol as an inhibitor of aquaporin-4 binding by NMO-IgG
por: Wang, Jie, et al.
Publicado: (2020)

Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians
por: Majed, Masoud, et al.
Publicado: (2016)

Altered fovea in AQP4-IgG–seropositive neuromyelitis optica spectrum disorders
por: Motamedi, Seyedamirhosein, et al.
Publicado: (2020)

Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder
por: Wingerchuk, Dean M., et al.
Publicado: (2021)

A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder
por: Berthele, Achim, et al.
Publicado: (2023)

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
por: Lennon, Vanda A., et al.
Publicado: (2005)

Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica
por: Duan, Tianjiao, et al.
Publicado: (2018)

Cytoprotective IgG antibodies in sera from a subset of patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder
por: Tradtrantip, Lukmanee, et al.
Publicado: (2021)

Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder
por: Akaishi, Tetsuya, et al.
Publicado: (2021)

Differences in Advanced Magnetic Resonance Imaging in MOG-IgG and AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders: A Comparative Study
por: Schmidt, Felix A., et al.
Publicado: (2020)

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
por: Marignier, Romain, et al.
Publicado: (2021)

Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder
por: Asgari, Nasrin, et al.
Publicado: (2017)

SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab
por: Bennett, Jeffrey L., et al.
Publicado: (2023)

Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case
por: Miao, Jing, et al.
Publicado: (2018)

Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica-Spectrum Disorders (NMO-SD): State-of-the-Art and Future Perspectives
por: Ceglie, Giulia, et al.
Publicado: (2020)

A Response to: Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder”
por: Wingerchuk, Dean M., et al.
Publicado: (2022)

Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder
por: Aktas, Orhan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p2b8nuj80luu9i5u28a9rqf1hd